ARCHIVES
VOL. 7, ISSUE 2 (2025)
Biotechnological interventions in neurodegenerative disorders: Exploring novel therapeutic strategies
Authors
Divya Yadav, Preety Sharma, Qasim Ansari, Vivek Kumar
Abstract
Neurodegenerative diseases such as Alzheimer’s and Parkinson’s are
characterized by the gradual loss of neurons, and diagnoses frequently happen
too late because of the shortcomings of current clinical tests. This research
emphasizes the importance of developing earlier and more precise diagnostic
techniques. Progress in neuroimaging technologies, including MRI and PET scans,
has enhanced diagnostic capabilities, and investigations into biomarkers found
in blood or cerebrospinal fluid could facilitate early identification.
Integrating these approaches with artificial intelligence may lead to the
development of predictive models, thereby enhancing diagnosis, treatment, and
overall patient outcomes. Psychedelics, specifically serotonergic substances
like LSD, psilocybin, and DOI (2,5-dimethoxy-4-iodoamphetamine), are becoming
more and more viable therapeutic options for the treatment of mental health
issues and neurodegenerative illnesses. Because neurodegenerative diseases
progress slowly and have few treatment choices, such as Alzheimer's and
Parkinson's, they provide serious obstacles. According to recent studies,
psychedelics have an impact on serotonin pathways, particularly those that
include 5-HT2A receptors, which are essential for improving neuroplasticity and
cognitive performance. Despite their therapeutic potential, challenges remain,
including legal restrictions and the need for further research to understand
the long-term effects and optimal dosing strategies. As the stigma surrounding
psychedelics diminishes, interdisciplinary collaboration among pharmacy,
biotechnology, and neuroscience is essential for advancing research and developing
personalized treatment approaches. Notwithstanding their potential as
therapeutics, there are still issues to be resolved, such as regulatory
limitations and the requirement for more study to determine the long-term
effects and ideal dose regimens. Interdisciplinary cooperation across pharmacy,
biotechnology, and neurology is crucial for expanding research and creating
individualized treatment plans as the stigma associated with psychedelics
fades. The study on psychedelics and neurodegenerative illnesses is reviewed in
this article, with a focus on the drugs' mechanisms of action, clinical
evidence, and potential future applications.
Download
Pages:53-57
How to cite this article:
Divya Yadav, Preety Sharma, Qasim Ansari, Vivek Kumar "Biotechnological interventions in neurodegenerative disorders: Exploring novel therapeutic strategies". International Journal of Biotechnology and Microbiology, Vol 7, Issue 2, 2025, Pages 53-57
Download Author Certificate
Please enter the email address corresponding to this article submission to download your certificate.